Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study

Plasma Cytokine and Angiogenic Factor Profiling Identifies Markers Associated with Tumor Shrinkage in Early-Stage Non-Small Cell Lung Cancer Patients Treated with Pazopanib

(2010) P. G. Nikolinakos et al.   CANCER RESEARCH

Biomarkers as Predictors of Response to Treatment with Motesanib in Patients with Progressive Advanced Thyroid Cancer

(2010) Michael B. Bass et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

(Pre-)Clinical Pharmacology and Activity of Pazopanib, a Novel Multikinase Angiogenesis Inhibitor

(2010) P. Hamberg et al.   ONCOLOGIST

Biomarkers of angiogenesis and their role in the development of VEGF inhibitors

(2009) N Murukesh et al.   BRITISH JOURNAL OF CANCER

Baseline Vascular Endothelial Growth Factor Concentration as a Potential Predictive Marker of Benefit from Vandetanib in Non-Small Cell Lung Cancer

(2009) E. O. Hanrahan et al.   CLINICAL CANCER RESEARCH

Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules

(2009) George D. Demetri et al.   JOURNAL OF CLINICAL ONCOLOGY

Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)

(2009) Stefan Sleijfer et al.   JOURNAL OF CLINICAL ONCOLOGY

Distinct Patterns of Cytokine and Angiogenic Factor Modulation and Markers of Benefit for Vandetanib and/or Chemotherapy in Patients With Non–Small-Cell Lung Cancer

(2009) Emer O. Hanrahan et al.   JOURNAL OF CLINICAL ONCOLOGY

Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma

(2008) Brian I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY

A Randomized, Double-Blind, Phase IIa Dose-Finding Study of Vandetanib (ZD6474) in Japanese Patients With Non-Small Cell Lung Cancer

(2008) Katsuyuki Kiura et al.   Journal of Thoracic Oncology